BlueCross BlueShield of Tennessee Medical Policy Manual

Ramucirumab

NDC CODE(S)

00002-7669-XX Cyramza 100 MG/10ML SOLN (LILLY)

 

00002-7678-XX Cyramza 500 MG/50ML SOLN (LILLY)

DESCRIPTION

Ramucirumab is a recombinant human IgG1 monoclonal antibody.  As a vascular endothelial growth factor (VEGF) receptor 2 antagonist, ramucirumab binds specifically to VEGF receptor 2 or VEGFR2  This blocks the growth factor ligands VEGF-A, VEGF-C and VEGF-D from binding to the receptor which prevents ligand-stimulated activation of VEGFR2.  This inhibits ligand-induced proliferation and migration of endothelial cells to inhibit angiogenesis and supplying increased blood flow to tumors.  In this way ramucirumab prevents the growth of blood vessels necessary for tumor growth.  

POLICY

MEDICAL APPROPRIATENESS

INITIAL APPROVAL

RENEWAL CRITERIA

INDICATION(S)

DOSAGE & ADMINISTRATION

Gastric, gastroesophageal, and colorectal cancer

8 mg/kg every 14 days

NSCLC

10 mg/kg every 21 days

LENGTH OF AUTHORIZATION

Coverage will be provided for 6 months and may be renewed.

Refer to DOSAGE LIMITS below

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee’s Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers.  This Medical Policy relates only to the services or supplies described in it.  The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy.  For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed.  If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.

ADDITIONAL INFORMATION 

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

No controlled studies were found in the published literature that validate the use of ramucirumab for the treatment or prevention of any other condition or disease.

SOURCES

Lexicomp Online. (2018, February). AHFS DI. Ramucirumab. Retrieved June 08, 2018 from Lexicomp Online with AHFS.

MICROMEDEX Healthcare Series. Drugdex Evaluations. (2018, February). Ramucirumab. Retrieved June 08, 2018 from MICROMEDEX Healthcare Series.

National Comprehensive Cancer Network. (2018). NCCN Drugs & Biologics Compendium®. Ramucirumab. Retrieved June 08, 2018 from the National Comprehensive Cancer Network.

U. S. Food and Drug Administration. (2015, April). Center for Drug Evaluation and Research. Cyramza® (ramucirumab) injection for intravenous infusion. Retrieved June 11, 2018 from https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125477s011lbl.pdf.

ORIGINAL EFFECTIVE DATE:  6/14/2014

MOST RECENT REVIEW DATE:  8/14/2018

ID_MRx

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information.

 


DOSAGE LIMITS

Maximum billable units per dose and over time by indication as a Medical Benefit   1 billable unit = 5 mg

DIAGNOSIS

MAXIMUM UNITS

Gastric, gastroesophageal, and colorectal cancer

180 billable units every 14 days

Non-Small Cell Lung Cancer

240 billable units every 21 days